Abstract | BACKGROUND: MATERIAL AND METHODS: We enrolled 114 CHD patients in the study. Serum VEGF level was measured by enzyme-linked immunosorbent assay (ELISA). Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and Hs-CRP were also tested in patients. The patients were divided into 2 groups according to the level of VEGF. Kaplan-Meier curve was used to observe the differences in survival situation of patients of the 2 groups. Cox regression analysis was conducted to judge whether VEGF was an independent biomarker for prognosis in CHD. RESULTS: We included 104 patients for survival analysis. VEGF level in CHD patients was significantly lower than that of healthy individuals (P<0.05). In the analysis of basic information, we found differences in sex distribution and hypertension between groups (P<0.05 for both). Kaplan-Meier curve indicated that patients with low expression of VEGF presented with poor prognosis. The mortality rate of the low-expression group was 37.71%, higher than that of the high-expression group (14.3%). Cox analysis suggested that VEGF could serve as a biomarker for prognosis in CHD (HR: 3.014, P: 0.019). CONCLUSIONS: Low level of VEGF may predict poor clinical outcome of CHD patients after PCI treatment.
|
Authors | Xia Han, Lili Liu, Jiamin Niu, Jun Yang, Zengtang Zhang, Zhiqiang Zhang |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 21
Pg. 3247-51
(Oct 26 2015)
ISSN: 1643-3750 [Electronic] United States |
PMID | 26501555
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Cholesterol, HDL
- Cholesterol, LDL
- Triglycerides
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- C-Reactive Protein
|
Topics |
- Aged
- Biomarkers
(blood)
- C-Reactive Protein
(metabolism)
- Case-Control Studies
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Coronary Disease
(blood, mortality, therapy)
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Percutaneous Coronary Intervention
- Prognosis
- Proportional Hazards Models
- Treatment Outcome
- Triglycerides
(blood)
- Vascular Endothelial Growth Factor A
(blood)
|